Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients

被引：34

作者：

Reardon, David A.

Nayak, Lakshmi

Peters, Katherine B.

Clarke, Jennifer Leigh

Jordan, Justin T.

De Groot, John Frederick

Nghiemphu, Phioanh Leia

Kaley, Thomas Joseph

Colman, Howard

Gaffey, Sarah C.

Caruso, Victoria

Debruyne, Myriam Bednarek

Bhavsar, Chinmay

Molinaro, Annette M.

Smith, Timothy

Severgnini, Mariano

Wen, Patrick Y.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Univ Calif San Francisco, San Francisco, CA USA

[5] Massachusetts Gen Hosp, Boston, MA USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Neuro Oncol, Houston, TX USA

[7] Univ Calif Los Angeles, Los Angeles, CA USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] Hunstman Canc Inst, Salt Lake City, UT USA

[10] Harvard Med Sch, Dana Farber, Brigham & Womens Canc Ctr, Boston, MA USA

[11] UC San Francisco, San Francisco, CA USA

[12] Brigham & Womens Hosp, Boston, MA USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.2006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2006

引用

页数：1